Patents by Inventor Pradip Mukerji

Pradip Mukerji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8916154
    Abstract: Disclosed are antibodies that specifically recognize ?5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The ?5-desaturase-specific antibodies provide improved methods of detecting ?5-desaturase in a sample.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: December 23, 2014
    Assignee: Abbott Laboratories
    Inventors: Tapas Das, Suzette L. Pereira, Pradip Mukerji, Padmavathy Krishnan
  • Patent number: 8916361
    Abstract: The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., “?9-elongase”) and to uses thereof. In particular, ?9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid (EDA, 20:2n-6). The production of dihomo-?-linolenic acid (DGLA, 20:3n-6) from eicosadienoic acid (EDA, 20:2n-6), and arachidonic acid (AA, 20:4n-6) from dihomo-?-linolenic acid (DGLA, 20:3n-6) is then catalyzed by ?8-desaturase and ?5-desaturase, respectively. AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: December 23, 2014
    Assignee: Abbott Laboratories
    Inventors: Tapas Das, Pradip Mukerji, Padmavathy Krishnan, Amanda E. Leonard, Suzette L. Pereira
  • Patent number: 8796333
    Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: August 5, 2014
    Assignee: Abbott Laboratories
    Inventors: Debra L. Thomas, Pradip Mukerji
  • Patent number: 8785496
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: July 22, 2014
    Assignee: Abbott Laboratories
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
  • Patent number: 8785495
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: July 22, 2014
    Assignee: Abbott Laboratories
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
  • Patent number: 8778992
    Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: July 15, 2014
    Assignee: Abbott Laboratories
    Inventors: Debra L. Thomas, Pradip Mukerji
  • Patent number: 8778994
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: July 15, 2014
    Assignee: Abbott Laboratories
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
  • Patent number: 8778632
    Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 6 (i.e., “?6-desaturase”). In particular, ?6-desaturase may be utilized, for example, in the conversion of linoleic acid to ?-linolenic acid and in the conversion of ?-linolenic acid stearidonic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: July 15, 2014
    Assignee: Abbott Laboratories
    Inventors: Pradip Mukerji, Yung-Sheng Huang, Amanda E. Leonard, Suzette L. Pereira, Jennifer M. Thurmond
  • Patent number: 8778993
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: July 15, 2014
    Assignee: Abbott Laboratories
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
  • Patent number: 8722384
    Abstract: The present invention relates to fatty acid desaturases able to catalyze the conversion of oleic acid to linoleic acid, linoleic acid to ?-linolenic acid, or of alpha-linolenic acid to stearidonic acid. Nucleic acid sequences encoding desaturases, nucleic acid sequences which hybridize thereto, DNA constructs comprising a desaturase gene, and recombinant host microorganism or animal expressing increased levels of a desaturase are described. Methods for desaturating a fatty acid and for producing a desaturated fatty acid by expressing increased levels of a desaturase are disclosed. Fatty acids, and oils containing them, which have been desaturated by a desaturase produced by recombinant host microorganisms or animals are provided. Pharmaceutical compositions, infant formulas or dietary supplements containing fatty acids which have been desaturated by a desaturase produced by a recombinant host microorganism or animal also are described.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: May 13, 2014
    Assignees: Calgene LLC, Abbott Laboratories
    Inventors: Deborah Knutzon, Pradip Mukerji, Yung-Sheng Huang, Jennifer Thurmond, Sunita Chaudhary, Amanda Eun-Yeong Leonard
  • Patent number: 8609725
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: December 17, 2013
    Assignee: Abbott Laboratories
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
  • Publication number: 20130011498
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.
    Type: Application
    Filed: January 11, 2012
    Publication date: January 10, 2013
    Applicant: ABBOTT LABORATORIES
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
  • Patent number: 8247653
    Abstract: The present invention is related to isolated polynucleotides encoding a delta-8 desaturase, delta-8 desaturases encoded by the isolated polynucleotides, expression vectors containing the isolated polynucleotides, host cells containing the expression vectors and methods for producing delta-8 desaturases and polyunsaturated fatty acids.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: August 21, 2012
    Assignee: Abbott Laboratories
    Inventors: Tapas Das, Pradip Mukerji, Padmavathy Krishnan, Suzette L. Pereira
  • Publication number: 20120196829
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Application
    Filed: January 11, 2012
    Publication date: August 2, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
  • Publication number: 20120189709
    Abstract: Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of ?-hydroxy-?-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Debra L. Thomas, Pradip Mukerji
  • Publication number: 20120189715
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
  • Publication number: 20120189717
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
  • Publication number: 20120189714
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
  • Publication number: 20120189716
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
  • Publication number: 20120177752
    Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 12, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji